Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 1112345...10...Last »

AstraZeneca aims to offset drug setback at big cancer congress

After a big clinical trial setback in lung cancer, AstraZeneca will seek to rebuild its oncology reputation in September 2017 when it unveils full details of two key clinical trials tackling the disease in different ways.

Read More »

Advertising budget for Obamacare to be cut 90 percent: U.S. health agency

The U.S. Centers for Medicare and Medicaid Services said it plans to spend $10 million on advertising for the upcoming Obamacare open enrollment period that starts in November 2017, a sharp cut from the $100 million spent during 2016.

Read More »

Profit on $475,000 Novartis cancer drug could be a while coming

Novartis’s new gene-modifying cancer therapy’s $475,000-per-patient sticker price has drawn fire from advocate groups calling for cheaper drugs, but analysts said the Swiss drugmaker could initially struggle to break even.

Read More »

Arizona accuses drugmaker Insys of fraudulent opioid marketing

Arizona sued Insys Therapeutics Inc., accusing the drugmaker of engaging in a fraudulent marketing scheme aimed at increasing sales of a fentanyl-based cancer pain medicine called Subsys.

Read More »

Daiichi Sankyo Terminates $650 Million Deal With Charleston Laboratories

After three years Daiichi Sankyo called it quits regarding the company’s partnership with Charleston Laboratories and took a loss of about $250 million.

Read More »

Incyte Discloses Promising New Data in Combo Drug Trial With Merck & Co.’s Keytruda

Incyte Corporation will have an abstract published at the European Society for Medical Oncology (ESMO) meeting in early September with new and updated data from its ongoing Phase I/II trial of epacadostat in combination with Merck & Co.’s Keytruda in advanced melanoma.

Read More »

Daiichi Sankyo denies AstraZeneca takeover bid

Japanese drugmaker Daiichi Sankyo denied that it received a takeover bid during 2016 from Britain’s AstraZeneca.

Read More »

Amazon hit with lawsuit over eclipse glasses was hit with a proposed class action lawsuit by a couple who claims defective eclipse glasses purchased through the online retailer damaged their eyes.

Read More »

FDA Approves Austedo for Tardive Dyskinesia

Teva Pharmaceutical Industries Ltd. announced that the U.S. FDA approved Austedo (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults.

Read More »

Lack of REM sleep tied to increased risk of dementia

People who spend less time in deep, rapid eye movement (REM) sleep may be more likely to develop dementia than individuals who get better quality rest, a recent study suggests.

Read More »

Novartis gene therapy for leukemia wins U.S. approval

Novartis’ anticipated leukemia treatment Kymriah is the first gene therapy to receive U.S. marketing clearance.

Read More »

FDA Approves Actemra for CAR T Cell-Induced CRS

The U.S. FDA approved Genentech’s Actemra (tocilizumab) intravenous injection for the treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome in patients 2 years of age and older.

Read More »

Otonomy pulls plug on ear drug, shares nosedive

Otonomy Inc. suspended developing its drug for Meniere’s disease, a chronic disorder of the inner ear, after it failed a late-stage trial.

Read More »

Five Prime Terminates $460 Million Immuno-oncology Deal With SoCal Biotech Inhibrx

Two years after forging a collaborative and licensing agreement with Southern California-based Inhibrx LLC, Five Prime Therapeutics Inc. walked away from the deal that includes an early cancer drug candidate.

Read More »

Fired Pfizer Scientist Slated for 2 More Retractions, Bringing the Total to 7

After a former Pfizer employee’s publications came under question, the company launched a review of Min-Jean Yin’s publication history and pushed for two additional retractions.

Read More »

FDA approves Medicines Co.’s urinary tract infection drug

The U.S. Food and Drug Administration approved Medicines Co.’s antibacterial drug for patients with complicated urinary tract infections (cUTI).

Read More »

UK report plans boost for life sciences as Brexit looms

The British government has rekindled its industrial strategy, unveiled earlier in 2017 to prepare the economy for Brexit, with plans to boost the country’s pharmaceuticals sector via fresh investments and public-private collaborations.

Read More »

Storm Harvey could financially hurt already strained Houston hospitals

Structural improvements over the last decade to Houston hospitals have helped them to avoid devastation like Hurricane Katrina in New Orleans in 2005, but the pounding it received from Tropical Storm Harvey is expected to financially hobble many already strained Texas medical centers.

Read More »

FDA approves Cyltezo, a biosimilar to Humira

The FDA approved Boehringer Ingelheim Pharmaceuticals’ Cyltezo, a biosimilar to Humira, in a pre-filled syringe for treating chronic inflammatory diseases.

Read More »

Noble Announces Global Collaboration with BD to Provide Advanced Patient Onboarding Solutions for Line of Safety and Shielding Systems

Noble, a leader in biopharmaceutical onboarding and device training, announced a global collaboration with BD (Becton, Dickinson and Company), a leading global medical technology company, for developing patient onboarding solutions including demonstration devices.

Read More »

Page 1 of 1112345...10...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2018 Focus: Agency Profiles, Manny Awards and Annual Review


Ad Right Bottom

Main Navigation